株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

分子細胞遺伝学市場の分析:用途別、製品別、最終用途別、技術別、セグメント別の予測

Molecular Cytogenetics Market Analysis Report By Application (Oncology, Personalized Medicine), By Product, By End Use, By Technology (FISH, Immunochemistry, Karyotyping), And Segment Forecasts, 2018 - 2025

発行 Grand View Research, Inc. 商品コード 370508
出版日 ページ情報 英文 236 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
分子細胞遺伝学市場の分析:用途別、製品別、最終用途別、技術別、セグメント別の予測 Molecular Cytogenetics Market Analysis Report By Application (Oncology, Personalized Medicine), By Product, By End Use, By Technology (FISH, Immunochemistry, Karyotyping), And Segment Forecasts, 2018 - 2025
出版日: 2018年02月22日 ページ情報: 英文 236 Pages
概要

当レポートでは、世界の分子細胞遺伝学市場について調査分析し、市場概要、セグメント別の市場の見通し、競合情勢、主要企業などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 調査手法

第3章 分子細胞遺伝学市場の変数、動向、範囲

  • 市場区分・範囲
  • SWOT分析:要因別
  • ファイブフォース分析
  • 自動化:需要と実装
  • サービスのコスト
  • コストの比較:技術別
  • サービスの需要と特質
  • 主要サービス:契約別
  • サービス提供の機会
  • 診断向けサービス
  • 研究向けサービス

第4章 分子細胞遺伝学市場:用途別の見通し・動向分析

  • 用途別の動向分析
  • 普及率・成長見通しマッピング
  • 遺伝性疾患
  • 腫瘍学
  • 個別化医療
  • その他

第5章 分子細胞遺伝学市場:製品別の見通し・動向分析

  • 製品別の動向分析
  • 普及率・成長見通しマッピング
  • 計器
  • 消耗品
  • ソフトウェア・サービス

第6章 分子細胞遺伝学市場:最終用途別の見通し・動向分析

  • 最終用途別の動向分析
  • 普及率・成長見通しマッピング
  • 臨床検査室・研究所
  • 臨床細胞遺伝学
  • 病院・病理研究所
  • 学術研究機関
  • 製薬・バイオテクノロジー企業
  • その他

第7章 分子細胞遺伝学市場:技術別の見通し・動向分析

  • 技術別の動向分析
  • 普及率・成長見通しマッピング
  • 比較ゲノムハイブリダイゼーション (CGH)
  • 蛍光in situハイブリダイゼーション (FISH)
  • 免疫組織化学
  • 染色体分析
  • その他

第8章 分子細胞遺伝学市場:地域別の見通し・動向分析

  • 市場シェア:地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 戦略の枠組み
  • 市場参入分類
  • 企業の市場シェア分析
  • 企業プロファイル
    • BIOVIEW
    • Danaher
    • MetaSystems
    • Agilent Technologies, Inc.
    • Abbott
    • Bio-Rad Laboratories, Inc.
    • Illumina, Inc.
    • Oxford Gene Technology
    • F. Hoffmann-La Roche Ltd
    • PerkinElmer Inc.
    • Quest Diagnostics Incorporated
    • Applied Spectral Imaging
    • Biological Industries USA, Inc.
    • CytoTest
    • Cytognomix
    • Genial Genetics
    • Diagnostic Cytogenetics, Inc.(DCI)
    • 病院/独立系研究所/大学/学術機関など
図表

List of Tables

  • TABLE 1: Prices for chromosome and/or FISH analysis
  • TABLE 2: Prices for cytogenetics services at University of Colorado Cancer Center
  • TABLE 3: Cytogenetics Unit Service List
  • TABLE 4: Cost comparison for chromosome testing of miscarriage specimens
  • TABLE 5: Average costs for cytogenetics testing for Idiopathic Learning Disability in U.K.
  • TABLE 6: Average costs for karyotype testing in the U.S.
  • TABLE 1: Comparison of the types of chromosomal abnormalities that can be detected by karyotype and array CGH
  • TABLE 2: Current method of choice for required tests associated with specific tumor types
  • TABLE 3: Demographics of patients undergoing (Dilation and Curettage) D&C for first-trimester miscarriage
  • TABLE 4 : ISH test panels for hematology/oncology available with Singapore General Hospital
  • TABLE 5 : lgorithm following positive NIPS results for prenatal diagnostics
  • TABLE 6 : verage number of cytogenetics tests performed by hospitals/laboratories annually
  • TABLE 7 : linical indications and techniques employed by cytogenetics laboratories
  • TABLE 8 : ighly assessed/cited papers published in molecular cytogenetics
  • TABLE 9 : xample of some genomic disorders that can be detected by chromosomal microarray analysis
  • TABLE 10: North America molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 11: North America molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 12: North America molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 13: North America molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 14: North America comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 15: North America karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 16: U.S. molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 17: U.S. molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 18: U.S. molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 19: U.S. molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 20: U.S. comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 21: U.S. karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 22: Canada molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 23: Canada molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 24: Canada molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 25: Canada molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 26: Canada comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 27: Canada karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 28: Europe molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 29: Europe molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 30: Europe molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 31: Europe molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 32: Europe comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 33: Europe karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 34: Germany molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 35: Germany molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 36: Germany molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 37: Germany molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 38: Germany comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 39: Germany karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 40: U.K. molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 41: U.K. molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 42: U.K. molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 43: U.K. molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 44: U.K. comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 45: U.K. karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 46: Asia Pacific molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 47: Asia Pacific molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 48: Asia Pacific molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 49: Asia Pacific molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 50: Asia Pacific comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 51: Asia Pacific karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 52: Japan molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 53: Japan molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 54: Japan molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 55: Japan molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 56: Japan comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 57: Japan karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 58: China molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 59: China molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 60: China molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 61: China molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 62: China comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 63: China karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 64: Latin America molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 65: Latin America molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 66: Latin America molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 67: Latin America molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 68: Latin America comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 69: Latin America karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 70: Brazil molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 71: Brazil molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 72: Brazil molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 73: Brazil molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 74: Brazil comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 75: Brazil karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 76: MEA molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 77: MEA molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 78: MEA molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 79: MEA molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 80: MEA comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 81: MEA karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 82: South Africa molecular cytogenetics market estimates & forecasts, by application, 2014 - 2025 (USD Million)
  • TABLE 83: South Africa molecular cytogenetics market estimates & forecasts, by product, 2014 - 2025 (USD Million)
  • TABLE 84: South Africa molecular cytogenetics market estimates & forecasts, by end-use, 2014 - 2025 (USD Million)
  • TABLE 85: South Africa molecular cytogenetics market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 86: South Africa comparative genomic hybridization market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
  • TABLE 87: South Africa karyotyping market estimates & forecasts, by technology, 2014 - 2025 (USD Million)

List of Figures

  • FIG. 1: Market summary
  • FIG. 2: Market research process
  • FIG. 3: Information procurement
  • FIG. 4: Primary research pattern
  • FIG. 5: Market research approaches
  • FIG. 6: Value chain based sizing & forecasting
  • FIG. 7: QFD modelling for market share assessment
  • FIG. 8: Market trends & outlook
  • FIG. 9: Market segmentation & scope
  • FIG. 10: Market driver relevance analysis (Current & future impact)
  • FIG. 11: FDA-approved pharmacogenomics biomarker in drug labeling as of 2016
  • FIG. 1 : stimated new cancers, female, 2016
  • FIG. 2 : stimated new cancers, male, 2016
  • FIG. 3 : istribution of persons aged 60 years or above, by region, 2017 & 2050
  • FIG. 4 : arket restraint relevance analysis (Current & future impact)
  • FIG. 5 : WOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 6 : orter's Five Forces Analysis
  • FIG. 7 : olecular cytogenetics market: Application outlook key takeaways
  • FIG. 8 : lobal Molecular cytogenetics market: Application movement analysis
  • FIG. 9 : enetration & growth prospect mapping for Application, 2016
  • FIG. 10: Global genetic disorders market, 2014 - 2025 (USD Million)
  • FIG. 11: Global oncology market, 2014 - 2025 (USD Million)
  • FIG. 12: Global personalized medicine market, 2014 - 2025 (USD Million)
  • FIG. 13: Global other applications market, 2014 - 2025 (USD Million)
  • FIG. 14: Molecular cytogenetics market: Product outlook key takeaways
  • FIG. 15: Global molecular cytogenetics market: Product movement analysis
  • FIG. 16: Penetration & growth prospect mapping for Product, 2016
  • FIG. 17: Global instruments market, 2014 - 2025 (USD Million)
  • FIG. 18: Global consumables market, 2014 - 2025 (USD Million)
  • FIG. 19: Global software & services market, 2014 - 2025 (USD Million)
  • FIG. 20: Molecular cytogenetics market: End-use outlook key takeaways
  • FIG. 21: Global molecular cytogenetics market: End-use movement analysis
  • FIG. 22: Penetration & growth prospect mapping for end-use, 2016
  • FIG. 23: New cancer cases, U.S.
  • FIG. 24: Global clinical & research laboratories market, 2014 - 2025 (USD Million)
  • FIG. 25: Global hospitals & pathology laboratories market, 2014 - 2025 (USD Million)
  • FIG. 26: Global academic research institutes market, 2014 - 2025 (USD Million)
  • FIG. 27: Global pharmaceutical and biotechnology companies market, 2014 - 2025 (USD Million)
  • FIG. 28: Global other end users market, 2014 - 2025 (USD Million)
  • FIG. 29: Molecular cytogenetics market: Technology outlook key takeaways
  • FIG. 30: Advantages & limitations: Molecular cytogenetic analysis
  • FIG. 31: Comparison of cytogenetic techniques for identifying chromosomal abnormalities
  • FIG. 32: Advantages & limitations: Molecular cytogenetic analysis
  • FIG. 33: Advantages & limitations: Conventional cytogenetic analysis
  • FIG. 34: Global molecular cytogenetics market: Technology movement analysis
  • FIG. 35: Penetration & growth prospect mapping for Technology, 2016
  • FIG. 36: Global comparative genomic hybridization market, 2014 - 2025 (USD Million)
  • FIG. 37: Global array-based comparative genomic hybridization market, 2014 - 2025 (USD Million)
  • FIG. 38: Global standard comparative genomic hybridization market, 2014 - 2025 (USD Million)
  • FIG. 39: Global fluorescence in situ hybridization market, 2014 - 2025 (USD Million)
  • FIG. 40: Global immunohistochemistry market, 2014 - 2025 (USD Million)
  • FIG. 41: Global karyotyping market, 2014 - 2025 (USD Million)
  • FIG. 42: Global spectral karyotyping market, 2014 - 2025 (USD Million)
  • FIG. 43: Global virtual karyotyping market, 2014 - 2025 (USD Million)
  • FIG. 44: Global other techniques market, 2014 - 2025 (USD Million)
  • FIG. 45: Regional market place: Key takeaway
  • FIG. 46: Molecular cytogenetics regional outlook, 2015 & 2025
  • FIG. 47: North America molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 48: U.S molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 49: Canada molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 50: Europe molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 51: Germany molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 52: U.K. molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 53: Asia Pacific molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 54: Japan molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 55: China molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 56: Latin America molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 57: Brazil molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 58: Middle East & Africa molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 59: South Africa molecular cytogenetics market, 2014 - 2025 (USD Million)
  • FIG. 60: Strategy framework
  • FIG. 61: Participant categorization
  • FIG. 62: Company market share analysis, product manufacturers 2016
  • FIG. 63: Company market share analysis, Service providers 2016
目次
Product Code: GVR-1-68038-023-1

The global molecular cytogenetics market size is expected to reach USD 3. 8 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 10.4% CAGR during the forecast period. Mapping of human genome, coupled with continuous technological advancements in cytogenetic techniques, has enabled researchers to gain insight into the disease-causing mechanism at a genomic as well as cellular level. Development in molecular technologies has helped in bridging the gap between molecular biology and cytogenetics, which was not possible using conventional cytogenetic techniques.

There is a continuous growth in awareness, and consequent adoption, of genetic tests for disease prognosis. These tests also help in designing further treatment regimes for widespread chromosomal abnormalities. This is sure to boost market growth.

Incorporation of high throughput sequencers in cytogenetic analysis is expected to significantly enhance market growth in the coming years. A number of researchers and scientists have begun converging cytogenetics laboratories with NGS as they complement each other. Hence, with exponential decline in sequencing price, this market is expected to grow at a lucrative pace.

However, ambiguous regulatory and reimbursement scenario in certain regions pertaining to implementation of genetic tests is expected to hamper the adoption of molecular cytogenetic techniques to a certain extent.

Further key findings from the report suggest:

  • Oncology held the largest share in the market in 2016 owing to the ability of CGH technology to facilitate in-depth studies for cancer etiology
  • Use of molecular cytogenetics in personalized medicine development is expected to grow lucratively during the forecast period. This is majorly due to a continuous shift toward targeted therapies for effective disease management
  • Requirement of consumables in the entire cytogenetics process is attributive for the largest share of this product category
  • Ongoing research projects for developing treatment regimen of different genetic conditions have allowed clinical and research laboratories to gain a significant share in the market
  • Pharmaceutical and biotech companies are expected to be a key source of revenue in the coming years. This is mainly because a number of pharmaceutical companies have expanded their business in the field of personalized medicine
  • Illumina, Inc.; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; and Oxford Gene Technology are some prominent companies in the market. They are involved in development and commercialization of cytogenetics techniques
  • Some major service providers are Weill Cornell Medicine; WiCell Research Institute, Inc.; ARUP Laboratories; and Integrated Systems Engineering S.r.l.

Table of Content

Chapter 1: Executive Summary

  • 1.1. Market Snapshot

Chapter 2: Research Methodology

  • 2.1. Information Procurement
  • 2.2. Information or Data Analysis
  • 2.3. Market Formulation & Validation

Chapter 3: Molecular Cytogenetics Market Variables, Trends & Scope

  • 3.1. Market Segmentation & Scope
    • 3.1.1. Market driver analysis
      • 3.1.1.1. Growing implementation of pharmacogenomics in personalized disease management and drug development
      • 3.1.1.2. Rising cancer cases
      • 3.1.1.3. Gradual advancements in cytogenetic techniques
      • 3.1.1.3.1. Transition from array based technology to NGS technology
      • 3.1.1.4. Growth in gene-based prediction of genetic abnormalities
      • 3.1.1.5. Increasing importance molecular cytogenetic in crop improvement
      • 3.1.1.6. Aging population & its vulnerability to chronic diseases
    • 3.1.2. Market restraint analysis
      • 3.1.2.1. High cost of instruments has restricted the adoption of cytogenetic techniques in developing and emerging nations
      • 3.1.2.2. Lack of skilled personnel
      • 3.1.2.3. Ambiguous regulatory & reimbursement scenario
  • 3.2. Molecular Cytogenetics -Swot Analysis, By Factor(Political & Legal, Economic And Technological)
  • 3.3. Industry Analysis-Porter's
  • 3.4. Automation in Cytogenetic Laboratory: Demand and Implementation
    • 3.4.1. Demand
      • 3.4.1.1. Demand for development of automated sequencing technology:
    • 3.4.2. Implementation
  • 3.5. Costs of cytogenetics services offered by prominent players operating in this space
  • 3.6. Cost comparison based on technique used in cytogenetic analysis
  • 3.7. Service demand and the nature of services provided
  • 3.8. Major service based contracts in the market
  • 3.9. Opportunities with respect to service offerings in cytogenetics
  • 3.10. Services for diagnostics
  • 3.11. Services for research

Chapter 4: Molecular Cytogenetics: Application Estimates & Trend Analysis

  • 4.1. Molecular Cytogenetics Market: Application Movement Analysis
  • 4.2. Penetration & Growth Prospect Mapping for Application, 2016
  • 4.3. Genetic Disorders
    • 4.3.1. Global genetic disorders market, 2014-2025(USD Million)
  • 4.4. Oncology
    • 4.4.1. Global oncology market, 2014-2025(USD Million)
  • 4.5. Personalized Medicine
    • 4.5.1. Global personalized medicine market, 2014-2025(USD Million)
  • 4.6. Other Applications
    • 4.6.1. Global other applications market, 2014-2025(USD Million)

Chapter 5: Molecular Cytogenetics: Product Estimates & Trend Analysis

  • 5.1. Global Molecular Cytogenetics Market: Product Movement Analysis
  • 5.2. Penetration & Growth Prospect Mapping for Product, 2016
  • 5.3. Instruments
    • 5.3.1. Global instruments market, 2014-2025(USD Million)
  • 5.4. Consumables
    • 5.4.1. Global consumables market, 2014-2025(USD Million)
  • 5.5. Software & Services
    • 5.5.1. Global software & services market, 2014-2025(USD Million)

Chapter 6: Molecular Cytogenetics: End-use Estimates & Trend Analysis

  • 6.1. Molecular Cytogenetics Market: End-use Movement Analysis
  • 6.2. Penetration & Growth Prospect Mapping for End-use, 2016
  • 6.3. Clinical & Research Laboratories
  • 6.4. Clinical Cytogenetics
    • 6.4.1. New cancer cases, U.S.
    • 6.4.2. Global clinical & research laboratories market, 2014-2025(USD Million)
  • 6.5. Hospitals & Pathology Laboratories
    • 6.5.1. Global hospitals & pathology laboratories market, 2014-2025(USD Million)
  • 6.6. Academic Research Institutes
    • 6.6.1. Global academic research institutes market, 2014-2025(USD Million)
  • 6.7. Pharmaceutical and Biotechnology Companies
    • 6.7.1. Global pharmaceutical and biotechnology companies market, 2014-2025(USD Million)
  • 6.8. Other End Users
    • 6.8.1. Global other end users market, 2014-2025(USD Million)

Chapter 7: Molecular Cytogenetics: Technology Estimates & Trend Analysis

  • 7.1. Global Molecular Cytogenetics Market: Technology Movement Analysis
    • 7.1.1. Comparative analysis of technologies
      • 7.1.1.1. Comparative analysis of various molecular cytogenetic techniques
      • 7.1.1.2. Comparative analysis of conventional and molecular cytogenetic techniques
  • 7.2. Penetration & Growth Prospect Mapping for Technology, 2016
  • 7.3. Comparative Genomic Hybridization
    • 7.3.1. Global comparative genomic hybridization market, 2014-2025(USD Million)
    • 7.3.2. Array-based comparative genomic hybridization
      • 7.3.2.1. Global array-based comparative genomic hybridization market, 2014-2025(USD Million)
    • 7.3.3. Standard comparative genomic hybridization
      • 7.3.3.1. Global standard comparative genomic hybridization market, 2014-2025(USD Million)
  • 7.4. Fluorescence In Situ Hybridization(FISH)
    • 7.4.1. Global fluorescence in situ hybridization market, 2014-2025(USD Million)
  • 7.5. Immunohistochemistry
    • 7.5.1. Global immunohistochemistry market, 2014-2025(USD Million)
  • 7.6. Karyotyping
    • 7.6.1. Global karyotyping market, 2014-2025(USD Million)
    • 7.6.2. Spectral karyotyping
      • 7.6.2.1. Global spectral karyotyping market, 2014-2025(USD Million)
    • 7.6.3. Virtual karyotyping
      • 7.6.3.1. Global virtual karyotyping market, 2014-2025(USD Million)
  • 7.7. Other Techniques
    • 7.7.1. Global other techniques market, 2014-2025(USD Million)

Chapter 8: Molecular Cytogenetics: Regional Estimates & Trend Analysis, by Application, Product, End-use, & Technology

  • 8.1. Molecular Cytogenetics Market Share By Region, 2015 & 2025
  • 8.2. North America
    • 8.2.1. North America molecular cytogenetics market, 2014-2025(USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. molecular cytogenetics culture market, by application, 2014-2025(USD Million)
      • 8.2.2.2. U.S. molecular cytogenetics culture market, by product, 2014-2025(USD Million)
      • 8.2.2.3. U.S. molecular cytogenetics culture market, by end-use, 2014-2025(USD Million)
      • 8.2.2.4. U.S. molecular cytogenetics culture market, by technology, 2014-2025(USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.2.3.2. Canada molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.2.3.3. Canada molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.2.3.4. Canada molecular cytogenetics market, by technology,2014-2025(USD Million)
  • 8.3. Europe
    • 8.3.1. Europe molecular cytogenetics market, 2014-2025(USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Germany molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.3.2.2. Germany molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.3.2.3. Germany molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.3.2.4. Germany molecular cytogenetics market, by technology,2014-2025(USD Million)
    • 8.3.3. U.K.
      • 8.3.3.1. U.K. molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.3.3.2. U.K. molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.3.3.3. U.K. molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.3.3.4. U.K. molecular cytogenetics market, by technology,2014-2025(USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific molecular cytogenetics market, 2014-2025(USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.4.2.2. Japan molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.4.2.3. Japan molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.4.2.4. Japan molecular cytogenetics market, by technology,2014-2025(USD Million)
    • 8.4.3. China
      • 8.4.3.1. China molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.4.3.2. China molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.4.3.3. China molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.4.3.4. China molecular cytogenetics market, by technology,2014-2025(USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America molecular cytogenetics market, 2014-2025(USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.5.2.2. Brazil molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.5.2.3. Brazil molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.5.2.4. Brazil molecular cytogenetics market, by technology,2014-2025(USD Million)
  • 8.6. Middle East & Africa
    • 8.6.1. Middle East & Africa molecular cytogenetics market, 2014-2025(USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa molecular cytogenetics market, by application, 2014-2025(USD Million)
      • 8.6.2.2. South Africa molecular cytogenetics market, by product, 2014-2025(USD Million)
      • 8.6.2.3. South Africa molecular cytogenetics market, by end-use, 2014-2025(USD Million)
      • 8.6.2.4. South Africa molecular cytogenetics market, by technology,2014-2025(USD Million)

Chapter 9: Competitive Landscape

  • 9.1. Strategy Framework
  • 9.2. Market Participation Categorization
  • 9.3. Company market share analysis
    • 9.3.1. Company size
    • 9.3.2. Product portfolio
    • 9.3.3. Geographical presence
    • 9.3.4. Mergers and collaborations
    • 9.3.5. Distribution networks
    • 9.3.6. Segment coverage
    • 9.3.7. Conclusion
  • 9.4. Company Profiles
    • 9.4.1. BIOVIEW
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Danaher
      • 9.4.2.1. Company overview
      • 9.4.2.1.1. Leica Biosystems Nussloch GmbH
      • 9.4.2.2. Financial performance
      • 9.4.2.2.1. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. MetaSystems
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Agilent Technologies, Inc.
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. Abbott
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Bio-Rad Laboratories, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Illumina, Inc.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Oxford Gene Technology
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. F. Hoffmann-La Roche Ltd
      • 9.4.9.1. Company overview
      • 9.4.9.1.1. Genentech, Inc.
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Financial performance
      • 9.4.9.4. Product benchmarking
      • 9.4.9.5. Strategic initiatives
    • 9.4.10. PerkinElmer Inc.
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Quest Diagnostics Incorporated
      • 9.4.11.1. Company overview
      • 9.4.11.1.1. Sonora Quest Laboratories
      • 9.4.11.2. Financial performance
      • 9.4.11.2.1. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Product benchmarking
      • 9.4.11.5. Strategic initiatives
    • 9.4.12. Applied Spectral Imaging
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. Biological Industries USA, Inc.
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. CytoTest
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Cytognomix
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
    • 9.4.16. Genial Genetics
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. Diagnostic Cytogenetics, Inc.(DCI)
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
    • 9.4.18. Hospital/standalone laboratory/University/Academic institute based cytogenetic services
      • 9.4.18.1. Weill Cornell Medicine
      • 9.4.18.1.1. Company overview
      • 9.4.18.1.2. Financial performance
      • 9.4.18.1.3. Service benchmarking
      • 9.4.18.2. UCLA Health-UCLA Pathology and Laboratory Medicines
      • 9.4.18.2.1. Company overview
      • 9.4.18.2.2. Financial performance
      • 9.4.18.2.3. Service benchmarking
      • 9.4.18.3. OHSU School of Medicine-Molecular and Medical Genetics
      • 9.4.18.3.1. Company overview
      • 9.4.18.3.2. Financial performance
      • 9.4.18.3.3. Service benchmarking
      • 9.4.18.4. Integrated Systems Engineering S.r.l.
      • 9.4.18.4.1. Company overview
      • 9.4.18.4.2. Financial performance
      • 9.4.18.4.3. Product benchmarking
      • 9.4.18.5. WiCell Research Institute, Inc.
      • 9.4.18.5.1. Company overview
      • 9.4.18.5.2. Financial performance
      • 9.4.18.5.3. Product benchmarking
      • 9.4.18.6. Virtual Scientific
      • 9.4.18.6.1. Company overview
      • 9.4.18.6.2. Financial performance
      • 9.4.18.6.3. Product benchmarking
      • 9.4.18.7. UW Cytogenetic Services
      • 9.4.18.7.1. Company overview
      • 9.4.18.7.2. Financial performance
      • 9.4.18.7.3. Service benchmarking
      • 9.4.18.8. Genesis Laboratories Inc.
      • 9.4.18.8.1. Company overview
      • 9.4.18.8.2. Financial performance
      • 9.4.18.8.3. Product benchmarking
      • 9.4.18.9. Calgary Laboratory Services
      • 9.4.18.9.1. Company overview
      • 9.4.18.9.2. Financial performance
      • 9.4.18.9.3. Product benchmarking
      • 9.4.18.10. Neogenomics
      • 9.4.18.10.1. Company overview
      • 9.4.18.10.2. Financial performance
      • 9.4.18.10.3. Product benchmarking
      • 9.4.18.11. ARUP Laboratories
      • 9.4.18.11.1. Company overview
      • 9.4.18.11.2. Financial performance
      • 9.4.18.11.3. Product benchmarking
      • 9.4.18.11.4. Strategic initiatives
      • 9.4.18.12. South West Thames Regional Genetics Service
      • 9.4.18.12.1. Company overview
      • 9.4.18.12.2. Financial performance
      • 9.4.18.12.3. Service benchmarking
Back to Top